Cargando…

88. Fostamatinib for the Treatment of Hospitalized Patients With COVID-19 Who Required Oxygen Supplementation: Results of a Phase 3 Trial

BACKGROUND: Severe COVID-19 is linked to hyperactivation of the host immune response involving signaling through multiple spleen tyrosine kinase (SYK) pathways. Fostamatinib is an orally administered potent and selective inhibitor of SYK that has been approved in the US, Canada, Japan, and Europe fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gotur, Deepa B, Malik, Anuj, Markovtsov, Vadim, Yan, Lucy, Dummer, Wolfgang, Mallat, Ziad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677048/ http://dx.doi.org/10.1093/ofid/ofad500.004

Ejemplares similares

561. Phase 3 Trial of Fostamatinib for the Treatment of COVID-19: Repurposing an Immunomodulatory Drug Previously Approved for Immune Thrombocytopenia
por: Mallat, Ziad, et al.
Publicado: (2021)

Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib
por: Cooper, Nichola, et al.
Publicado: (2021)

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials
por: Bussel, James, et al.
Publicado: (2018)

Clinical Trial to Evaluate an Approved ITP Therapy Targeting Spleen Tyrosine Kinase (SYK) for Prevention and Treatment of COVID-19 Related Complications
por: Dummer, Wolfgang, et al.
Publicado: (2020)

Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs
por: Harbi, Maan H., et al.
Publicado: (2022)

Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents
por: Lengel, Dave, et al.
Publicado: (2015)

Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
por: Boccia, Ralph, et al.
Publicado: (2020)

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
por: Bussel, James B., et al.
Publicado: (2019)

Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study
por: Kuter, David J., et al.
Publicado: (2022)

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406
por: Matsukane, Ryosuke, et al.
Publicado: (2022)

Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib
por: Innao, Vanessa, et al.
Publicado: (2023)

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

P1614: TAPERING SCHEME AND SUSTAINED RESPONSE IN PATIENTS WITH ITP TREATED WITH FOSTAMATINIB
por: Mingot-Castellano, María Eva, et al.
Publicado: (2023)

Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies
por: Martin, P., et al.
Publicado: (2016)

Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
por: Tabassum, Neha, et al.
Publicado: (2020)

The Cardiovascular Risks of Fostamatinib in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
por: Chen, Yuehong, et al.
Publicado: (2021)

Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion
por: Lucchesi, Alessandro, et al.
Publicado: (2023)

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib
por: Rolf, Michael G, et al.
Publicado: (2015)

Neoplasm Risk in Patients With Rheumatoid Arthritis Treated With Fostamatinib: A Systematic Review and Meta-analysis
por: Chen, Yuehong, et al.
Publicado: (2022)

Sustained response off therapy after fostamatinib: A chronic refractory ITP case report
por: Auteri, Giuseppe, et al.
Publicado: (2023)

P1613: REAL-WORLD USE OF FOSTAMATINIB IN FRANCE. INTERIM RESULTS OF A NATIONAL REGISTRY.
por: Moulis, Guillaume, et al.
Publicado: (2023)

CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH COVID-19 ON EXTRACORPOREAL MEMBRANE OXYGENATION THERAPY: EXAMINING THE THREE SURGES
por: PADHYE, AKHILESH, et al.
Publicado: (2021)

Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic
por: Strich, Jeffrey R, et al.
Publicado: (2020)

Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
por: Saha, Sovan, et al.
Publicado: (2022)

Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration
por: Wang, Mingyao, et al.
Publicado: (2022)

Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
por: Kang, Yaqi, et al.
Publicado: (2019)

Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series
por: Hughes, David M., et al.
Publicado: (2021)

The Efficacy and Safety of Fostamatinib in Elderly Patients with Immune Thrombocytopenia: A Single-Center, Real-World Case Series
por: Liu, Jessica, et al.
Publicado: (2022)

Eco-Friendly UPLC–MS/MS Method for Determination of a Fostamatinib Metabolite, Tamatinib, in Plasma: Pharmacokinetic Application in Rats
por: Ezzeldin, Essam, et al.
Publicado: (2021)

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia
por: Herman, SEM, et al.
Publicado: (2013)

Myd88 Is Required for an Antibody Response to Retroviral Infection
por: Browne, Edward P., et al.
Publicado: (2009)

A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury
por: Kost-Alimova, Maria, et al.
Publicado: (2020)

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies
por: Martin, Paul, et al.
Publicado: (2016)

RALE SCORE AS A PROGNOSTICATION TOOL FOR PATIENTS WITH COVID-19 ON ECMO
por: PADHYE, AKHILESH, et al.
Publicado: (2021)

The cilia protein IFT88 is required for spindle orientation in mitosis
por: Delaval, Benedicte, et al.
Publicado: (2011)

CCDC88B is required for pathogenesis of inflammatory bowel disease
por: Fodil, Nassima, et al.
Publicado: (2017)

PB2019: PHASE 1B CLINICAL STUDY OF IRAK 1/4 INHIBITION FOR LOW-RISK MYELODYSPLASTIC SYNDROMES REFRACTORY/RESISTANT TO PRIOR THERAPIES: A TRIAL IN PROGRESS
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

Myeloid differentiation factor 88 is required for resistance to Neospora caninum infection
por: Mineo, Tiago W.P., et al.
Publicado: (2009)

EXM-88-01: 10/03/88
por: Martucci, P, et al.
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_dqcb70dv4ujp45co7nkfc6ste4